Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.35 CAD | -2.25% |
|
-3.33% | +42.62% |
Jun. 26 | Kneat.com, Korber Pharma Consulting Join Forces on Digitalization Efforts | MT |
Jun. 26 | Kneat Brief: Kneat and Korber Pharma Consulting Partnering On Digitalization | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+42.62% | 279M | - | ||
+35.25% | 394B | B- | ||
+34.23% | 237B | B+ | ||
+7.58% | 158B | B | ||
+27.94% | 64.98B | D+ | ||
+38.74% | 39.29B | C+ | ||
+163.92% | 28.58B | D+ | ||
-15.93% | 24.05B | B+ | ||
+28.01% | 21.89B | B- | ||
+48.66% | 14.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- KSI Stock
- Ratings kneat.com, inc.